Palvella Therapeutics, Inc.
PVLA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583648
In the last 90 days, Palvella Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 196 institutions reported holding it in 13F filings for Q2 2026, worth $2.15B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:53 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Mar 31, 2025 | Mar 27, 2024 | Mar 29, 2023 | Jan 24, 2022 |
| Revenue | – | – | $42.8M | $25.9M | $31.4M |
| Operating expenses | $38.6M | $14.1M | $72.6M | $69.4M | $83.2M |
| Research and development | $22.8M | $8.15M | $41.8M | $53.0M | $66.7M |
| Selling, general and administrative | $15.8M | $5.94M | $16.9M | $16.4M | $16.6M |
| Operating income | -$38.6M | -$14.1M | -$29.8M | -$43.5M | -$51.8M |
| Interest expense | $0 | $430.0K | – | – | – |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$41.7M | -$17.4M | -$24.5M | -$33.3M | -$45.7M |
| EPS, basic | $-3.71 | $-7.83 | $-0.27 | $-0.45 | $-0.71 |
| EPS, diluted | $-3.71 | $-7.83 | – | – | $-0.71 |
| Weighted shares, basic | 11.3M | 2.23M | 90.1M | 74.2M | 64.5M |
| Weighted shares, diluted | 11.3M | 2.23M | – | – | 64.5M |
| Margins and growth | |||||
| Operating margin | – | – | -69.5% | -167.8% | -165.0% |
| Net margin | – | – | -57.3% | -128.5% | -145.6% |
| Revenue growth, year over year | – | – | +65.3% | −17.6% | +7.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Mar 31, 2025 | Mar 27, 2024 | Mar 29, 2023 | Jan 24, 2022 |
| Cash and equivalents | $58.0M | $83.6M | $17.4M | $38.6M | $117.8M |
| Short-term investments | – | – | $8.97M | $20.5M | – |
| Accounts receivable | $0 | $358.0K | $572.0K | $5.81M | $3.31M |
| Total current assets | $59.0M | $88.2M | $38.7M | $73.4M | $127.6M |
| Property, plant and equipment | – | – | $0 | $17.0M | $19.1M |
| Total assets | $59.6M | $88.2M | $38.7M | $95.5M | $153.6M |
| Accounts payable | $4.59M | $4.59M | $3.37M | $4.15M | $8.61M |
| Total current liabilities | $11.3M | $12.0M | $11.9M | $36.6M | $50.6M |
| Total liabilities | $31.6M | $25.6M | $11.9M | $67.6M | $102.8M |
| Shareholders' equity | $28.0M | $62.6M | $26.8M | $27.9M | $50.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Mar 31, 2025 | Mar 27, 2024 | Mar 29, 2023 | Jan 24, 2022 |
| Operating cash flow | -$25.0M | -$10.8M | -$53.8M | -$59.9M | -$7.66M |
| Capital expenditures | – | – | $171.0K | $1.04M | $949.0K |
| Free cash flow | – | – | -$54.0M | -$61.0M | -$8.61M |
| Depreciation and amortization | – | – | $1.90M | $2.77M | – |
| Stock-based compensation | $6.40M | $830.0K | $3.35M | $4.40M | $5.21M |
| Investing cash flow | – | – | $12.0M | -$21.2M | -$949.0K |
| Financing cash flow | -$660.0K | $87.1M | $19.8M | $7.21M | $59.1M |
| Net change in cash | -$25.6M | $76.3M | -$21.2M | -$79.1M | $47.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | 7.8% | 17.0% | 16.6% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 2, 2026 | 14.6M | +23.5% | SEC |
| Jul 31, 2026 | 14.4M | +30.3% | SEC |
| May 1, 2026 | 14.3M | +29.7% | SEC |
| Mar 25, 2026 | 14.3M | +29.9% | SEC |
| Nov 1, 2025 | 11.8M | +796.5% | SEC |
| Aug 8, 2025 | 11.1M | +737.7% | SEC |
| May 9, 2025 | 11.1M | +737.4% | SEC |
| Mar 25, 2025 | 11.0M | −88.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.